We are live on ! Find out more
EVGN icon

Evogene

15 hedge funds and large institutions have $52M invested in Evogene in 2014 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

0.25% more ownership

Funds ownership: 1.98%2.23% (+0.25%)

0% more funds holding

Funds holding: 1515 (0)

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

20% less capital invested

Capital invested by funds: $65.1M → $52M (-$13M)

Holders
15
Holders Change
Holders Change %
0%
% of All Funds
0.4%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
4
Reduced
4
Closed
2
Calls
Puts
Net Calls
Net Calls Change

EVGN Hedge Fund Activity: Q4 2014 in Review

15 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q4 2014, worth a combined $52M — down 20% from $65.1M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new EVGN positions and 2 closed out — a net gain of 1 holder — while 4 added to existing stakes and 4 trimmed.

The largest buyer was Goldman Sachs, adding an estimated $2.81M. The largest seller was Credit Suisse, exiting entirely with an estimated $1.32M sold.

  • 15 institutional investors held Evogene (EVGN) as of Q4 2014, unchanged from Q3 2014.
  • Funds reported $52M of Evogene stock for Q4 2014, down 20% quarter-over-quarter.
  • 3 funds opened new Evogene positions in Q4 2014 and 2 closed out, a net change of +1 holder.
  • The largest Evogene buyer in Q4 2014 was Goldman Sachs, an estimated $2.81M added.
  • The largest Evogene seller in Q4 2014 was Credit Suisse, an estimated $1.32M sold.

Based on aggregated 13F filings for Q4 2014.